PROVECTUS BIOPHARMACEUTICALS
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer.
PROVECTUS BIOPHARMACEUTICALS
Industry:
Biotechnology Health Care Medical
Address:
Knoxville, Tennessee, United States
Country:
United States
Website Url:
http://www.provectusbio.com
Total Employee:
1+
Status:
Active
Contact:
(800) 733-1121
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Official Site Inspections
http://www.provectusbio.com Semrush global rank: 5.63 M Semrush visits lastest month: 1.5 K
- Host name: cloudhost-433585.us-midwest-1.nxcli.net
- IP address: 209.87.159.189
- Location: Lansing United States
- Latitude: 42.7348
- Longitude: -84.6245
- Metro Code: 551
- Timezone: America/Detroit
- Postal: 48917
More informations about "Provectus Biopharmaceuticals"
Corporate Governance - Provectus Biopharmaceuticals, Inc.
I would like to receive investor related information about Provectus Biopharmacuticals. CORPORATE GOVERNANCE. Board of Directors. Management. Strategic Advisory BoardSee details»
Provectus Biopharmaceuticals - Crunchbase Company Profile
Provectus Biopharmaceuticals is a clinical-stage biotechnology company that develops new therapies for the treatment of skin cancer, liver cancer, and breast cancer.See details»
PVCT Company Description - Stock Analysis
Nov 27, 2024 Company profile for Provectus Biopharmaceuticals, Inc. (PVCT) with a description, list of executives, contact details and other key facts.See details»
Corporate Presentation - Provectus Biopharmaceuticals, Inc.
I would like to receive investor related information about Provectus Biopharmacuticals. Corporate Presentation. Igniting the Embers of HopeSee details»
Provectus Biopharmaceuticals - Craft
Sep 12, 2024 Provectus Biopharmaceuticals has 5 employees across 2 locations and $557.71 k in annual revenue in FY 2023. See insights on Provectus Biopharmaceuticals including office …See details»
Provectus Biopharmaceuticals - Overview, News & Similar
Apr 18, 2024 Who is Provectus Biopharmaceuticals. Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing …See details»
Company Provectus Biopharmaceuticals, Inc. - MarketScreener.com
Apr 2, 2017 Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are …See details»
Provectus Biopharmaceuticals CEO and key executive team - Craft
Provectus Biopharmaceuticals's Chief Operating Officer, Board Member is Bruce Horowitz. Other executives include Ed Pershing, Chairman of the Board; Eric Wachter, Chief Technology …See details»
Provectus Biopharmaceuticals - VentureRadar
Similar Companies: Agastiya Biotech USA n/a Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. …See details»
Provectus Biopharmaceuticals Announces Exclusive Worldwide …
Mar 27, 2024 Provectus Biopharmaceuticals Inc. New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and …See details»
Provectus Biopharmaceuticals Announces Exclusive Worldwide
Mar 27, 2024 In 2022, the International Nonproprietary Names (“INN”) Expert Committee of the World Health Organization (the “WHO”) selected RBS for the nonproprietary name of the …See details»
Provectus Biopharmaceuticals Announces World Health
Nov 2, 2022 Dominic Rodrigues, Vice Chair of Provectus’ Board of Directors, said “The World Health Organization’s International Nonproprietary Names system has facilitated the name of …See details»
Annual Reports - Provectus Biopharmaceuticals, Inc.
Oct 1, 2015 ANNUAL REPORTS. 2024 Proxy Statement. 2023 Annual Report. 2023 Proxy Statement. 2022 Annual Report. 2022 Proxy Statement. 2021 Annual Report. 2021 Proxy …See details»
Provectus Biopharmaceuticals Announces Presentation of …
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational …See details»
Provectus Biopharmaceuticals Announces Stockholder Approval to ...
Jun 26, 2023 The International Nonproprietary Names Expert Committee of the World Health Organization selected “rose bengal sodium” for the nonproprietary name of the Company’s …See details»
Provectus Biopharmaceuticals Provides Updated Data on Cancer ...
KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer …See details»
Provectus Biofuels, Inc. - Cleanest Fuels on Earth | Clean energy ...
Provectus Biofuels Inc. is a clean energy technology developer incorporated in British Columbia. We integrate our licensed patented process technology with proven advancements in …See details»
Provectus Biopharmaceuticals Announces Decision to Not …
KNOXVILLE, TN, December 12, 2022 (GLOBE NEWSWIRE) – Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the …See details»
Provectus Biopharmaceuticals Announces Presentation of …
KNOXVILLE, TN, November 6, 2023 (GLOBE NEWSWIRE) – Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational …See details»